Pulmonary vascular disease & thromboembolism
Prevention of Venous Thromboembolism after Total Hip or Knee Replacement
Authors' conclusion
Aspirin prophylaxis after total hip or knee arthroplasty was not noninferior to rivaroxaban or warfarin with respect to death or symptomatic VTE. Warfarin and rivaroxaban were not noninferior to aspirin for safety. (Funded by the Patient-Centered Outcomes Research Institute; PEPPER ClinicalTrials.gov number, NCT02810704.).
Study context
- Population
- Patients undergoing elective hip or knee arthroplastyrandomized, 15,317 included in the primary per-protocol analysis · 7,214 (hip arthroplasty, per-protocol) · 8,103 (knee arthroplasty, per-protocol)
- Participants
- 18,883 patients
- Comparison
- Aspirin vs warfarin vs rivaroxaban for venous thromboembolism (VTE) prophylaxis
- Aspirinn = 6,090
- Warfarinn = 4,231
- Rivaroxabann = 4,996
- Primary endpoint
- Composite primary effectiveness outcome (death from any cause or symptomatic VTE)
- Follow-up
- 6 months
Methodological detailsrandomized, blinded outcome evaluation
- Randomized
- Blinded outcome evaluation
Primary result
As reported in the abstract
Composite primary effectiveness outcome (death from any cause or symptomatic VTE)
Risk difference, percentage points (95% CI)
Aspirinvs rivaroxabanpairwise risks 1.24% and 0.94%
0.30(−0.20 to 0.81)
Aspirinvs warfarinpairwise risks 1.24% and 1.01%
0.23(−0.34 to 0.81)
Warfarinvs rivaroxabanpairwise risks 1.13% and 1.10%
0.03(−0.57 to 0.63)
Safety
Primary safety outcome (bleeding, reoperation for wound problems, or myocardial infarction) · 6 months
| Outcome | Aspirin | Warfarin | Rivaroxaban | Risk difference (percentage points) (95% CI) | |
|---|---|---|---|---|---|
| Rivaroxabanvs aspirinPairwise risks 3.70% and 3.02% · primary safety outcome · Intention-to-treat analyses yielded similar results | 2.91% | 3.36% | 3.48% | 0.68 (−0.04 to 1.41) | |
| Warfarinvs aspirinPairwise risks 3.65% and 2.88% · primary safety outcome · Intention-to-treat analyses yielded similar results | 0.77 (−0.04 to 1.58) | ||||
| Rivaroxabanvs warfarinPairwise risks 3.59% and 3.61% · primary safety outcome · Intention-to-treat analyses yielded similar results | −0.02 (−0.89 to 0.85) | ||||
| −1012Difference, percentage points (linear scale) |
Original publication
Prevention of Venous Thromboembolism after Total Hip or Knee Replacement. N Engl J Med. Published 12 November 2026. doi:10. 1056/ nejmoa2602435
Composed by AI from the published abstract and checked against it. How Briefs are made →